2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 11, 2015

9:00AM-10:30AM: Abstract Number: 3242

A Comprehensive Method for Using Sensewear MiniTM Monitors to Explore Differences in Ambulatory Activities in People Living with and without Early Rheumatoid Arthritis: Moving Beyond Measuring Total Steps

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3243

A Randomized Controlled Trial for a Physical Activity Intervention for RA Fatigue

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3236

Circulating Cytokine/Chemokine Concentrations Predict Cancer Mortality in Men with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects VI: Death Be Not Proud-Mortality and Treatment Outcomes in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk)

9:00AM-10:30AM: Abstract Number: 3237

Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Rheumatoid Arthritis - Clinical Aspects VI: Death Be Not Proud-Mortality and Treatment Outcomes in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk)

9:00AM-10:30AM: Abstract Number: 3241

Do Boosters Support Long-Term Physical Activity Maintenance after an Intervention? a Systematic Review

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3246

Does Loss of a Community Walking Speed Lead to More Symptoms of Depression in Knee OA? a Trajectory Analysis from the Osteoarthritis Initiative

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3244

Evaluation of a Self-Directed Walking Program in Hispanics with Arthritis

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3245

Factors Associated with Physical Activity in Older Children with Juvenile Idiopathic Arthritis

ARHP V: Physical Activity

9:00AM-10:30AM: Abstract Number: 3240

Improved Survival in Rheumatoid Arthritis: A General Population-Based Study

Rheumatoid Arthritis - Clinical Aspects VI: Death Be Not Proud-Mortality and Treatment Outcomes in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk)

9:00AM-10:30AM: Abstract Number: 3239

Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years

Rheumatoid Arthritis - Clinical Aspects VI: Death Be Not Proud-Mortality and Treatment Outcomes in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk)

9:00AM-10:30AM: Abstract Number: 3238

The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection

Rheumatoid Arthritis - Clinical Aspects VI: Death Be Not Proud-Mortality and Treatment Outcomes in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk)

11:00AM-12:30PM: Abstract Number: 3254

A Clinical Risk Score to Predict Functional Disability at 1 Year in an Early Rheumatoid Arthritis Inception Cohort

Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

11:00AM-12:30PM: Abstract Number: 3255

Brain White Matter Integrity: A Future Biomarker for Rheumatoid Arthritis Related Fatigue?

Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

11:00AM-12:30PM: Abstract Number: 3270

Correction of Limb Length Inequality in Adults with Knee or Hip Symptoms: A Pilot Study

ARHP VI: Physical Function and Disability

11:00AM-12:30PM: Abstract Number: 3247

Dietary Intake of Omega-3 Fatty Acids and Vitamin C and D Associate with Decreased Pain, Independent of Inflammation, in MTX Treated Early RA Patients

Pain: Clinical Aspects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].